VistaGen Therapeutics Q1 2025 Adj EPS $(0.35) Beats $(0.41) Estimate, Sales $84.00K Miss $300.00K Estimate
VistaGen Therapeutics Q1 2025 Adj EPS $(0.35) Beats $(0.41) Estimate, Sales $84.00K Miss $300.00K Estimate
VistaGen Therapeutics 2025年第一季度調整後的每股收益爲-0.35美元，超過了-0.41美元的預期，銷售額爲8.4萬美元，未達到30萬美元的預期
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 14.63 percent. The company reported quarterly sales of $84.00 thousand which missed the analyst consensus estimate of $300.00 thousand by 72.00 percent. This is a 52.70 percent decrease over sales of $177.60 thousand the same period last year.
Vistagen Therapeutics (納斯達克: VTGN) 報告每股虧損0.35美元，比分析師共識預期(虧損0.41美元)高14.63%。該公司報告本季度銷售額爲8.4萬元，比分析師共識預期(30萬元)低72.00％。這是相對於去年同期銷售額的下降52.70％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。